Urinary Bladder Cancer Clinical Trials

7 recruiting

Urinary Bladder Cancer Trials at a Glance

8 actively recruiting trials for urinary bladder cancer are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Amsterdam, Beijing, and Burlington. Lead sponsors running urinary bladder cancer studies include Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lahey Clinic, and Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Browse urinary bladder cancer trials by phase

Treatments under study

About Urinary Bladder Cancer Clinical Trials

Looking for clinical trials for Urinary Bladder Cancer? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Urinary Bladder Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Urinary Bladder Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Intravesical Gem/Doce in Patients With NMIBC

Urinary Bladder Cancer
University of Arizona25 enrolled1 locationNCT05644041
Recruiting

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

CancerUrothelial CancerUrinary Bladder Cancer+1 more
Lahey Clinic500 enrolled1 locationNCT00872495
Recruiting

Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor

Cognitive DeclineUrinary Bladder CancerGeneral Anesthesia+8 more
Osijek University Hospital42 enrolled1 locationNCT07165236
Recruiting

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Breast CancerMelanomaSquamous Cell Carcinoma of Head and Neck+4 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1,000 enrolled1 locationNCT05621837
Recruiting
Phase 2

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Urinary Bladder Cancer
Zhujiang Hospital41 enrolled1 locationNCT04861584
Recruiting

Multicentric Prospective T1 Urinary Bladder Cancer Registry

T1 Urinary Bladder Cancer
Medical University of Vienna700 enrolled1 locationNCT05792033
Recruiting
Phase 1Phase 2

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

Urinary Bladder CancerInvasive Bladder Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)50 enrolled3 locationsNCT03844256
Recruiting
Phase 2

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Bladder CancerUrinary Bladder CancerBladder Neoplasms+2 more
Peking University First Hospital54 enrolled1 locationNCT05072600